Clinical trial · Interventional
Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma
An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma
NCT02345408CI-TRIAL-00086521completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CCX872-B | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CCX872-B
- description
- 150 mg once or twice daily given orally for at least 12 weeks
- interventionNames
- Drug: CCX872-B
Primary outcomes (2)
- measure
- progression-free survival
- timeFrame
- 24 weeks
- measure
- subject incidence of Grade 3 or 4 adverse events
- timeFrame
- 24 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed non-resectable pancreatic adenocarcinoma with or without metastases * Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2 * Anticipated life expectancy ≥ 12 weeks * Radiographically measurable disease acc. to RECIST 1.1 * Use of adequate contraception (as described in protocol) * Ability to provide written informed consent and comply with study requirements Exclusion Criteria: * Received other cancer treatment or investigational drug within 4 weeks prior to screening * Women who are pregnant or breastfeeding * Had major surgery within 4 weeks of first dose of study drug * Inadequate liver, renal or bone marrow function within 2 weeks of first dose * Serious concurrent illness, altered medical status or any uncontrolled medical condition * Any infection requiring antibiotic or anti-viral treatment within 4 weeks of screening * Known active HIV, HBV or HCV infection * Inability to swallow tablets * History or presence of any medical condition or disease which, in the opinion of the investigator, may place the subject at unacceptable risk for study participation
References
Publications (0)
Data not yet available
No reference posted for this study.